Search

Purpose: To estimate and compare annual prevalence and incidence, and demographic characteristics of patients with ulcerative colitis (UC) in Japan and the United States (US). Methods: All patients with UC were identified from large employment-based healthcare claims databases (Japan Medical Data Center [JMDC] in Japan and IBM MarketScan Commercial Claims and Encounters database [CCAE] in the US), from 2010 to 2019. Cases were confirmed using International Classification of Disease-9/10 codes with/without Anatomical Therapeutic Chemical codes. Annual age-standardized prevalence and incidence rates were estimated for the JMDC by direct standardization using the CCAE as the standard population. Results: Patients with UC were younger in Japan than in the US and men were affected more than women, whereas the reverse was true in the US. Annual prevalence per 100,000 population increased significantly from 5 in 2010 to 98 in 2019 in Japan and from 158 to 233 in the US. Prevalence increased in men more than in women and in all age groups in Japan, whereas increases were observed similarly in men and women, and in the 6 to < 65-year age groups in the US. Annual incidence per 100,000 person-years increased significantly over time in both sexes and in all age groups in Japan, with higher increases in women and in ≥ 18 year-olds. UC incidence rates did not change over time in the US. Conclusion: Ten-year trends in epidemiology of UC differ between Japan and the US. The data point to a growing disease burden in both countries that warrants investigation of measures for prevention and treatment. [ABSTRACT FROM AUTHOR]

Background: In Japan, several research studies have used administrative claims databases. However, no study has compared the studies conducted in each database. Objective: We assessed the type, design, and research area of each research study using the administrative databases in Japan to illustrate the suitability of the database used for the types of research studies. Methods: We reviewed studies from four administrative claims databases (the Japanese National Database of Health Insurance Claims and Specific Health Checkups [NDB]; the DPC Study Group database [DPC]; Japan Medical Data Center [JMDC]; and Medical Data Vision [MDV]). The PubMed database was searched from January 2015 to October 2020. We assessed the type, design, and research area of the abstract or full text of each research study. Results: Overall, 643 studies were included. The number of studies increased from 59 in 2015 to 171 in 2020. Descriptive studies accounted for 62.7% (42 studies) of the studies from the NDB, while the treatment effectiveness studies accounted for 81.7% (211 studies) of the studies from the DPC database and were the most common in the JMDC and MDV. Cohort studies accounted for only 17.9% of the studies on NDB but 45.5% on DPC. The most common research area was medicine, general, and internal medicine (53 studies, 8.4%). Conclusions: The type and design of the studies conducted differed in each database and were influenced by the characteristics of the database used. In the future, it may be necessary to integrate various real-world data databases to increase their comprehensiveness. [ABSTRACT FROM AUTHOR]

Purpose: To estimate the nationwide, longitudinal prevalence and incidence rates and assess treatment patterns of non-infectious uveitis (NIU) in Japan. Study design: A retrospective study. Methods: Health insurance claims' data of patients with NIU were extracted from the Japan Medical Data Center (JMDC) database and analyzed descriptively (data extraction period, January 2011 to May 2017). Behçet's disease (BD), Vogt-Koyanagi-Harada (VKH) disease, and sarcoidosis were selected as the primary diseases of NIU. Results: From 2011 to 2016, the mean and median age of patients increased. Most (> 90%) patients were categorized as "undifferentiated NIU" (NIU without specific primary disease information after excluding BD-, VKH disease-, and sarcoidosis-associated NIU). Over 60% of patients with NIU were treated at non-hospital clinics, while the rest were treated at university, public, or other hospitals. The estimated prevalence rate of NIU was 386.5 per 100,000 persons (95% confidence interval [CI], 374.5–398.6) in 2011 and 439.3 per 100,000 persons (95% CI, 432.3–446.3) in 2016; the estimated incidence rate was 189.7 per 100,000 persons (95% CI, 181.2–198.5) in 2012 and 207.8 per 100,000 persons (95% CI, 202.2–213.5) in 2016. Most patients' prescribed uveitis drugs were ophthalmic drops over the first 6 months after patient presentation and entry into the JMDC database, followed by systemic corticosteroids. Conclusion: The estimated prevalence of NIU in Japan in recent years was approximately 400 with incidence of 200 per 100,000 persons. [ABSTRACT FROM AUTHOR]